SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

Coverage Information

Access and print SOLIRIS OneSource coverage information now.

Navigating the insurance landscape

Insurance coverage for SOLIRIS® (eculizumab) varies by payor type and plan. Briefly,

  • In the physician office, Medicare is likely to cover and reimburse for SOLIRIS when its use is considered reasonable. Under the current CMS Hospital Outpatient Prospective Payment System (HOPPS), SOLIRIS will be reimbursed separately under a pass-through process. Learn more about likely Medicare coverage in both the physician office and hospital settings.
     
  • Medicaid coverage varies by state Medicaid Agency for both physician office and hospital coverage. However, many agencies will cover and reimburse SOLIRIS in both settings following a coverage review. Learn more about likely Medicaid coverage in both the physician and hospital settings.
     
  • Commercial payors include employer health plans, individual plans, Medicare Advantage (Part C), and Medicaid managed care plans. SOLIRIS coverage varies by payor/plan, based on individual patient healthcare benefits. Learn more about what you may need to obtain commercial payor coverage for SOLIRIS.

Steps you can take to facilitate SOLIRIS coverage

Because PNH is rare, many payors lack a formal SOLIRIS coverage policy. More likely, they will assess each request according to the individual patient's medical need(s). The Alexion Case Manager can help with the following to ensure that your patients are reimbursed for their SOLIRIS treatment:

Contact a OneSource™ Case Manager at 1.888.SOLIRIS (1.888.765.4747) for additional information and support on denied claims. The Alexion Case Manager wil let you know if the patient has authorized sharing of health information and can also provide copies of the consent form for your files.

Next: Reimbursement


IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.